Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Acquires 1,882 SharesZolmax • 25 days ago
Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin purchased 1,882 shares of the firm's stock in a transaction dated Thursday, March 28th. The shares were...
Share to Feed
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval...
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval...
Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) Director Yezan Munther Haddadin bought 1,882 shares of Outlook Therapeutics stock in a transaction dated Thursday, March 28th. The stock was...
Outlook Therapeutics files for $300M mixed securities shelf...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Outlook Therapeutics (NASDAQ:OTLK Free Report) had its price target increased by HC Wainwright to $30.00 in a research note released on Monday morning, Benzinga reports. HC Wainwright...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
This is a Bullish indicator signaling OTLK's price could rise from here. Traders may explore going long the stock or buying call options...